Categories: NewsPharmaceutical

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company’s website.

About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.

Contacts:
Suzanne Harnett
sharnett@siga.com

and

Investors Media
Jennifer Drew-Bear, Edison Group
Jdrew-bear@edisongroup.com
Holly Stevens, CG Life
hstevens@cglife.com

Staff

Recent Posts

Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- BiOS - Hall D Booth #8430, Photonics West Hall…

8 hours ago

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

13 hours ago

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

14 hours ago

University of Phoenix and LinkedIn to host webinar on AI in nursing with skills and strategies for a new era of healthcare

January 22 virtual event "AI in Action: Skills and Strategies for a New Era of…

14 hours ago

Instinct Science Acquires ScribbleVet to Deliver the Next Generation of Intelligent-Native Veterinary Practice Management Software

The combination redefines PIMS by embedding AI, workflow, and clinical intelligence into a single system…

14 hours ago

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

19 hours ago